(Q34198408)

31 July 2017

1 reference

title

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications (English)

1 reference

31 July 2017

0 references

1 reference

M Epstein

1

1 reference

31 July 2017

1 April 2001

1 reference

American Journal of Kidney Diseases

31 July 2017

1 reference

31 July 2017

37

1 reference

31 July 2017

4

1 reference

31 July 2017

677-688

1 reference

Vasoactive hormones and renal sclerosis

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Understanding the nature of renal disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Systemic hypertension versus intraglomerular hypertension in progression

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Reversing glomerular hypertension stabilizes established glomerular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Plasma aldosterone concentrations in chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Mineralocorticoids, hypertension, and cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone: intracellular receptors in human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone (ALDO) increases transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Remodeling and reparation of the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Long-term treatment of mineralocorticoid excess syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Efficacy and tolerance of spironolactone in essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Antialdosterones: incidence and prevention of sexual side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Side-effects of spironolactone therapy in the hirsute woman

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Tolerance of spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Effect of aging on plasma renin and aldosterone in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Aldosterone and vascular damage

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

Vascular aldosterone in genetically hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2801%2980115-3

7 January 2021

10.1016/S0272-6386(01)80115-3

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11273866